Fig 1.

Dynamics of SFP values during the course of TB development and treatment, examined by E6+E7 and E6+E7+C14 IFN-γ ELISPOT assays. As shown in Table 6, PBL samples were collected at regular intervals from nine outpatients with PTB, during regular anti-TB treatment, and were monitored by E6+E7 and E6+E7+C14 IFN-γ ELISPOT assays. With the exception of patients 4 and 9, SFP values began to decrease, together with an amendment in TB symptoms, until a relatively low, almost normal, level was reached and maintained after 3 to 4 months. SFP, number of spot-forming cells/10⁶ peripheral blood mononuclear cells.